Resident core · Fellow evidence · Attending review

HIV and opportunistic infections

Diagnosis, ART, prevention, and the next steps in OI diagnosis and treatment.

Core 30–45 minAdvanced reference optionalVersion 1.3 · Edited November 10, 2026

Advanced fellow teaching is below

Complete the resident core or jump directly to the detailed teaching and reference sections.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

Link the HIV diagnosis, immune assessment, and immediate clinical problem

Resident core · 30–45 minutes with discussion

The resident cases turn on three questions: is this acute HIV, does the presenting illness change when ART should begin, and what care must continue after discharge? The advanced section compares treatment phases, maintenance criteria, newer therapies, and the evidence behind them.

A positive HIV test is the beginning of the assessment. HIV RNA, CD4 count, symptoms, medication history, and access to continuing treatment determine what needs to happen next.

Confirm the diagnosis without missing acute infection

Begin with a laboratory HIV-1/2 antigen-antibody test, followed by an HIV-1/HIV-2 differentiation assay when reactive. If the differentiation assay is negative or indeterminate, obtain HIV RNA to resolve possible acute infection. With a compatible recent exposure or acute retroviral syndrome, order RNA even when the screening test is negative.

Recent PrEP or PEP, especially a long-acting product, can change test interpretation and resistance risk. In a person taking PrEP with negative antibody testing, a low-positive RNA below 200 copies/mL needs confirmation on a new specimen before ART. At RNA ≥200 copies/mL during PrEP, prompt initiation of an effective, complete ART regimen is recommended while confirmation is pending.

Collect HIV RNA, CD4, genotype, hepatitis serologies, renal/hepatic assessment, and other indicated baseline studies. Screen for symptoms suggesting an OI. These studies usually can be collected while arranging rapid ART; do not create an avoidable delay in an otherwise appropriate patient.

Sources: early, baseline, initiation.

Start a complete ART regimen and identify the exceptions

For most people starting ART, an integrase inhibitor with two appropriate NRTIs is a standard approach. Common examples are bictegravir/TAF/FTC or dolutegravir with TAF/FTC or TDF/FTC when suitable. Selection depends on organ function, pregnancy, resistance risk, hepatitis B, interactions, and access.

Dolutegravir/lamivudine is a recommended initial option when HBV infection and relevant resistance have been excluded. The September 24, 2026 NIH update removed the previous baseline HIV RNA ceiling. Do not use it for rapid start while HBV and genotype results are pending. HIV/HBV coinfection generally requires two HBV-active components, usually tenofovir plus FTC or 3TC, in a fully suppressive HIV regimen. Stopping HBV-active drugs can precipitate hepatitis.

Prior long-acting cabotegravir (CAB-LA) PrEP raises the possibility of integrase resistance. If ART is needed before an integrase genotype is available, a boosted darunavir regimen with two appropriate nucleos(t)ide agents allows prompt treatment without assuming an integrase inhibitor will be active. Pregnancy and drug interactions affect the booster choice.

Timing matters: prompt ART is the usual approach, including during treatment of many OIs. Cryptococcal meningitis and TB meningitis require a separate timing plan because early immune recovery in the CNS can be harmful.

Sources: arv, hbv, initiation.

Use the syndrome to choose the first OI tests and treatment

Initial OI decisions in advanced HIV
SyndromeInitial evaluationManagement anchor
Subacute dyspnea and diffuse pulmonary opacitiesAssess oxygenation; obtain an appropriate respiratory specimen for Pneumocystis testing and evaluate other pulmonary causes.Start PCP treatment when suspicion is high. Steroids depend on hypoxemia, not the CD4 count alone.
Headache or meningitic symptomsConsider cryptococcus and TB; obtain serum/CSF studies and measure opening pressure when LP is safe.Cryptococcal meningitis needs combination induction therapy and active pressure management. An early repeat therapeutic LP merits consideration even if symptoms are mild or the initial opening pressure is low. For a person not already taking ART, the usual time to start is 4–6 weeks after antifungal treatment begins.
Focal neurologic signs or brain lesionsObtain brain imaging and consider toxoplasma, lymphoma, PML, TB, and other causes.Treat a likely toxoplasma presentation while setting a response checkpoint and an alternative-diagnosis plan.
Visual symptomsArrange urgent dilated ophthalmologic examination.CMV retinitis is an organ diagnosis. Plasma CMV PCR alone neither establishes nor excludes retinitis.
Fever, cytopenias, weight loss, or systemic illnessUse exposure and organ findings to evaluate histoplasmosis, MAC, TB, bacterial infection, and malignancy.Get syndrome-directed cultures and antigen/tissue tests. A prophylaxis dose is not adequate treatment of disseminated disease.

CD4 thresholds help prioritize possibilities but do not prove the diagnosis. Multiple infections can coexist. A worsening patient needs reassessment for treatment failure, another infection, toxicity, and IRIS.

Sources: pcp, crypto, toxo, cmv, histo, mac.

Treat PCP according to respiratory severity and plan what follows

For most adults with HIV-associated PCP, the preferred treatment is TMP-SMX for 21 days. Moderate or severe disease usually calls for IV treatment initially; oral treatment may be suitable for milder disease or after improvement. Renal function affects exposure. The regimen used to prevent PCP is not adequate treatment for active pneumonia.

Room-air PaO₂ below 70 mm Hg or an A–a gradient of at least 35 mm Hg identifies patients who benefit from adjunctive corticosteroids. Begin steroids promptly, ideally within 72 hours of starting PCP therapy. When feasible, ART begins within 2 weeks of the PCP diagnosis. Secondary prophylaxis follows immediately after treatment.

A rising oxygen requirement prompts a second look at coinfection, drug exposure, toxicity, and the expected early course. Potassium, renal function, blood counts, and rash help distinguish treatment toxicity from progression. The advanced section compares alternatives by severity.

Sources: pcp.

Separate primary prophylaxis, secondary maintenance, PrEP, and PEP

Four different prevention decisions
PurposeDecision anchor
Primary PCP prophylaxisFor a person not taking ART or starting ART, CD4 below 200 is an indication under the current NIH guidance. For someone already on ART, use the restart criteria in the detailed table.
Primary toxoplasma prophylaxisToxoplasma IgG positivity plus CD4 below 100 is the usual indication. TMP-SMX can cover both toxoplasma and PCP prophylaxis.
Primary MAC prophylaxisConsider at CD4 below 50 when effective ART will not start promptly or suppression is not achievable; exclude disseminated MAC first. It is not routinely needed with immediate effective ART.
Secondary maintenanceAfter an OI, use that disease’s own treatment-completion and immune-recovery criteria. Do not apply a primary-prophylaxis stopping rule automatically.
PrEPConfirm HIV-negative status, match the regimen to the exposure population, and arrange the required testing and follow-up. Oral and long-acting options have different eligibility and dosing schedules.
PEPWhen nonoccupational PEP is indicated after a substantial exposure, start it as soon as possible, ideally within 24 hours and no later than 72 hours. The course is 28 days. Baseline testing and follow-up are essential, but pending results must not delay the first dose.

Sustained viral suppression prevents sexual HIV transmission. Discuss this clearly while still addressing other STI prevention, immunizations, reproductive goals, and access to treatment.

Sources: pcp, toxo, mac, prep, pep, uu.

Check delivery and interactions before declaring the regimen ineffective

Ask whether the person has the medicines and can take them consistently. Review antacids and mineral supplements with integrase inhibitors, acid suppressants with rilpivirine, rifamycins, anticonvulsants, and all nonprescription products. Food requirements and absorption matter.

Recheck HIV RNA after treatment starts or changes according to the monitoring guideline, commonly within 4–8 weeks, and follow until suppressed. With persistent viremia, assess adherence, interactions, absorption, and resistance before changing therapy. Do not add a single active drug to a failing regimen.

Discharge planning should name the HIV clinician, provide uninterrupted medication access, specify pending-result ownership, and distinguish the ART, OI treatment, and prophylaxis stop or reassessment dates. Suppression is the start of ongoing preventive care.

Sources: monitor, failure, interactions.

Use three cases to identify the immediate decision

Case 1 · A discordant diagnostic sequence

A symptomatic patient with a recent exposure has a reactive antigen-antibody test and a negative differentiation assay.

Discuss the next action and the finding that would change it.

Discussion

The negative differentiation assay does not exclude acute HIV. HIV RNA resolves the next diagnostic question. Recent PrEP or PEP can alter the pattern; in particular, a low-positive RNA below 200 copies/mL with negative antibodies during PrEP needs confirmation on a new specimen before treatment.

Case 2 · Low CD4 with hypoxemic pneumonia

A patient with newly diagnosed HIV has CD4 42, diffuse opacities, and room-air PaO2 64 mm Hg.

Discuss the next action and the finding that would change it.

Discussion

With a room-air PaO₂ of 64 mm Hg, this patient meets the oxygen threshold for adjunctive steroids if PCP is suspected. Treatment should not wait for a respiratory specimen result when suspicion is high. Bacterial pneumonia and TB remain possible. If feasible, ART begins within 2 weeks of PCP diagnosis; secondary prophylaxis follows the acute course.

Case 3 · Meningitis changes the ART clock

A patient with advanced HIV has a positive CSF cryptococcal antigen and a high opening pressure.

Discuss the next action and the finding that would change it.

Discussion

The positive CSF antigen and elevated opening pressure make this a CNS infection. Urgent antifungal induction and therapeutic lumbar punctures address separate threats. Persistent signs of raised pressure call for prompt repeat drainage. Clinical response and CSF cultures guide the next treatment phase. If the person is not already taking ART, the usual time to start is 4–6 weeks after antifungal treatment begins.

State the HIV and OI plans as linked but separate decisions

Document the diagnostic status, HIV RNA/CD4, complete ART regimen and start date, OI diagnosis and treatment, ART-timing rationale, prophylaxis, monitoring, and follow-up access.

The advanced sections compare OI treatment phases, maintenance stopping criteria, and the populations studied in clinical trials.

Advanced teaching and detailed reference begin here

Additional cases and original studies below explore resistance, prevention, and OI management beyond the resident core.

HIV care begins with a diagnosis, an immune assessment, and a durable treatment plan

This case-based primer is for residents and ID fellows. The advanced section includes recent evidence and treatment updates. The first block covers HIV diagnosis, ART, prevention, and longitudinal care. The second is a practical guide to opportunistic infections (OIs) and related infections. All cases are fictional teaching examples.

Resident essentials

The resident core is above. The following sections explain how the involved organ, immune status, and treatment response change the next decision.

Advanced pathway

Add resistance, injectable treatment, ART timing controversies, and the original-trial discussion. Allow another 20-30 minutes.

After completing this module, you should be able to

  1. Interpret discordant HIV tests and select the next diagnostic test.
  2. Select an initial ART strategy using resistance history, HBV status, organ function, and interactions.
  3. Build a syndrome-directed OI evaluation and specify treatment, ART timing, and prophylaxis.
  4. Distinguish virologic failure, treatment toxicity, another diagnosis, and IRIS.
  5. Deliver a discharge and prevention plan that preserves medication access and follow-up.

Original clinical source review September 15, 2026. ART eligibility updated October 31, 2026. AI-assisted educational synthesis. This is educational material, not an institutional protocol. Local laboratory order names, drug access, reporting, and referral pathways require confirmation.

Use the testing sequence and recognize acute HIV before antibodies are fully detectable

HIV RNA reflects viral replication; CD4 count helps estimate immune vulnerability. A high CD4 count does not remove the indication for treatment, and a low CD4 count does not establish the cause of an acute illness. Acute HIV may resemble influenza, COVID-19, EBV/CMV mononucleosis, or secondary syphilis, with fever, rash, pharyngitis, lymphadenopathy, diarrhea, or aseptic meningitis. [1] [2]

Laboratory diagnosis and the next step
FindingInterpretationNext step
Reactive laboratory HIV-1/2 antigen-antibody assayA screening result, not the complete diagnosisPerform HIV-1/HIV-2 antibody differentiation.
Reactive screen and positive differentiationHIV established by the diagnostic algorithmObtain HIV RNA, CD4, and baseline evaluation; arrange ART.
Reactive screen and negative or indeterminate differentiationAcute HIV versus false-positive screeningHIV-1 RNA helps distinguish acute infection from a false-positive screen. Repeat testing on a new specimen when needed; persistent concern for HIV-2 requires HIV-2-specific evaluation. The next rows distinguish recent exposure from discordant results while taking PrEP.
Negative screen with recent exposure and compatible illnessWindow-period infection remains possibleOrder HIV RNA and arrange repeat testing.
Discordant testing while taking PrEPEarly infection, drug-modified infection, or false positivityDuring PrEP, negative antibody testing plus detectable (low-positive) quantitative HIV RNA below 200 copies/mL warrants repeat quantitative RNA and confirmatory antibody testing on a new specimen; obtain the results before starting ART in this specific setting. With RNA ≥200 copies/mL during PrEP, initiate effective complete ART while confirming the diagnosis. PEP-associated discordance also needs expert interpretation; this is not a universal waiting rule.
[1]
Ask specifically about prior oral and injectable PrEP, PEP, and the last injection date. Recent antiretroviral exposure can alter both the testing pattern and the resistance risk.

Use nonjudgmental language and confirm how the patient wants results communicated. HIV itself requires Standard Precautions. Add transmission-based precautions for the suspected accompanying pathogen, such as airborne precautions for pulmonary TB. [3]

Collect baseline studies without creating an unnecessary delay in ART

The first visit or inpatient consultation
TaskWhat to establish
HIV status and prior treatmentDiagnostic documentation; prior ART, PrEP/PEP, genotypes, interruptions, and current medication supply.
Virology and immunityHIV RNA and CD4. Genotype for reverse transcriptase and protease; add integrase testing for prior CAB PrEP, INSTI treatment failure, or suspected INSTI resistance.
Organ function and coinfectionCBC, renal and liver testing, urinalysis, lipids; hepatitis A immunity; HBV surface antigen, surface antibody, core antibody; HCV testing with RNA when indicated.
Prevention and special situationsPregnancy testing when relevant; site-specific STI testing and syphilis serology; TB screening after assessing for disease; Toxoplasma IgG when relevant to OI prevention and a G6PD activity result before dapsone or primaquine. HLA-B*5701 only if considering abacavir.
Clinical feasibilitySymptoms of CNS, pulmonary, ocular, or disseminated OI; drug interactions, swallowing and absorption, insurance/ADAP, transport, housing, mental health, substance use, and a confirmed follow-up clinician.
[4] [1] [5] [6]

Send specimens before ART when feasible. In a clinically suitable patient, do not wait for CD4 or genotype results to start an appropriate rapid-start regimen. If HBV results are pending, use a regimen with HBV activity. CNS cryptococcosis and TB meningitis are important exceptions to reflex immediate ART. [4] [7] [3]

Advanced HIV is a prompt to look for an OI, not an instruction to send every available PCR. Choose specimens from the involved organ and identify which result would change treatment.

Choose an effective complete regimen and account for the exceptions

HIV integrates into host DNA and persists in a reservoir that current ART does not eradicate. NRTIs and NNRTIs inhibit reverse transcription, INSTIs inhibit integration, and protease inhibitors prevent viral maturation. Ritonavir and cobicistat commonly serve as pharmacokinetic boosters; they are not interchangeable with an active drug in the regimen. Capsid and entry-directed agents have specialized roles. [8]

For most treatment-naive adults without prior long-acting cabotegravir exposure, recommended initial options include bictegravir/TAF/FTC, dolutegravir plus two nucleos(t)ide agents, or dolutegravir/lamivudine when the exclusions below do not apply. Here, TAF/TDF are tenofovir formulations, FTC is emtricitabine, and 3TC is lamivudine. Renal dysfunction, pregnancy, resistance, and interacting drugs can change the choice. [8]

Common adult ART strategies
Regimen or settingPractical useReason to choose differently
Bictegravir/FTC/TAFComplete single-tablet option for many adults starting ART, including a suitable rapid start.Review kidney function and cations. Rifampin is contraindicated. Prior CAB PrEP requires a resistance-informed approach. [9]
Dolutegravir plus TAF/FTC or TDF/FTCA three-drug option; kidney function influences the choice of tenofovir formulation and companion agents.DTG dosing changes with some inducers or resistance. Fixed-dose combinations are not interchangeable across renal categories. [8] [10]
Dolutegravir/lamivudine (DTG/3TC)Two-drug option for selected patientsThis two-drug regimen is not a rapid-start choice. It requires documented absence of chronic HBV infection and reverse-transcriptase genotype results excluding relevant resistance. The 2026 NIH update removed the former baseline RNA ceiling; it did not remove these exclusions. [8] [11]
HIV after CAB PrEPPrior CAB-LA PrEP calls for integrase resistance testing. If ART starts before results return, the interim strategy is boosted darunavir with TAF or TDF plus FTC or 3TC.Do not assume bictegravir or dolutegravir remains active. Pregnancy changes booster selection. [1]
HIV/HBV coinfectionThe usual fully suppressive HIV regimen includes TAF or TDF plus FTC or 3TC, providing HBV activity.FTC or 3TC alone is inadequate HBV treatment. If tenofovir cannot be used, add entecavir to fully suppressive HIV therapy. Avoid unplanned withdrawal of HBV-active drugs. [12]
Pregnancy or pregnancy planningStart promptly and consult the current perinatal recommendationsDo not withhold ART. Review pregnancy-specific pharmacokinetics and the complete regimen. [13]

Fellow and attending discussion

ART trial endpoints usually measure virologic suppression, not superiority in mortality. A switch study in already suppressed patients does not establish a rapid-start regimen. Distinguish the genetic barrier of a drug from the actual activity of the complete regimen against a patient’s archived virus. [8] [14]

Reconcile interactions and absorption before calling a regimen ineffective

High-yield medication problems
ProblemPractical response
Integrase inhibitors with magnesium/aluminum antacids, iron, calcium, or enteral feedsCheck the exact drug and administration schedule. Cation separation and food rules differ by product; ask pharmacy to document a feasible schedule.
Rifamycins with ARTUse the TB/ART interaction tables. Do not add rifampin to bictegravir, CAB/RPV, or a boosted PI regimen without redesigning treatment.
Ritonavir/cobicistat with corticosteroids, anticoagulants, statins, antiarrhythmics, or azolesA medication-level interaction check is mandatory. Inhaled or injected steroids also count.
Oral rilpivirine with acid suppression or insufficient foodPPIs are contraindicated with oral RPV; check food and H2-blocker timing. This absorption issue does not apply to injected RPV.
Rising creatinine after DTG/BIC or cobicistatA small early change may reflect inhibited creatinine secretion, but assess true AKI, urine findings, nephrotoxins, and the trend.
NPO, dysphagia, feeding tube, or ICU admissionVerify formulations and product-specific crushing/dissolving data. Avoid accidental partial ART or an unplanned long-acting treatment gap.
[15] [9] [8] [3]

Repeat HIV RNA about 4-8 weeks after initiation or a regimen change, then every 4-8 weeks until suppressed. Stable suppression generally permits monitoring every 3-4 months, sometimes every 6 months after sustained stability. Follow CD4 more closely when it determines OI prevention. [16]

For confirmed rebound at or above 200 copies/mL, assess access, adherence, interactions, and resistance. Obtain genotype while the failing regimen is still being taken, or preferably within 4 weeks of stopping oral ART. Review all historical resistance. A single low detectable result is not automatically failure. Do not add one active drug to a failing regimen. [14]

OI next steps start with the syndrome and severity

Second teaching block · OI diagnosis and treatment

Which organ is involved? How severe is the illness? These questions determine the initial treatment phase and whether rapid ART will help or harm. Formulation, organ function, pregnancy, and interacting drugs can change the regimen.

CD4 thresholds change probability; they are not exclusion rules. Bacterial infections and TB can occur at any CD4 count. Below 200, PCP becomes prominent; below 100, consider toxoplasmosis and cryptococcosis; below 50, disseminated MAC and CMV end-organ disease become more likely. Histoplasmosis is particularly important with advanced HIV and relevant geography. [6] [5] [7] [17] [18] [19] [3]

Syndrome-directed OI assessment
PresentationDiagnostic next stepsImmediate treatment or action
Subacute dyspnea, dry cough, hypoxemiaPulse oximetry, imaging; arterial blood gas when steroid threshold is uncertain. Induced sputum or BAL for PCP testing; assess bacterial pneumonia and TB concurrently.Treat suspected severe PCP promptly while obtaining confirmation. Add oxygen and indicated corticosteroids; isolate for TB if suspected.
Headache, meningitis, altered mentationNeurologic exam; imaging before LP when indicated. LP with opening pressure, cell count, glucose/protein, CrAg, and fungal culture; other tests guided by presentation.Treat the likely syndrome urgently; do not start ART reflexively before assessing cryptococcal/TB meningitis.
Focal deficit or seizureContrast MRI; Toxoplasma IgG; consider lymphoma, PML, TB, abscess, stroke. CSF only if safe.Treat presumed toxoplasmosis when supported; arrange early biopsy for atypical features or lack of response.
Floaters, scotoma, blurred visionUrgent dilated retinal examination; do not use plasma CMV PCR to rule out retinitis.Same-day ophthalmology; sight-threatening disease may need local plus systemic therapy.
Fever, wasting, cytopenias, high alkaline phosphataseBlood cultures; mycobacterial blood cultures, urine/serum Histoplasma antigen, imaging and tissue sampling as indicated. Consider lymphoma.In severe disseminated histoplasmosis, begin liposomal amphotericin B. Avoid macrolide prophylaxis while evaluating possible active MAC.
Odynophagia or persistent diarrheaAssess thrush, stool tests and exact panel coverage, medications, hydration. Endoscopy with biopsy when esophageal disease fails empiric treatment or CMV colitis is suspected.Systemic antifungal for esophageal candidiasis; rehydration and organism-directed enteric therapy. CMV DNAemia alone does not establish colitis.
[6] [7] [5] [20] [18] [19] [17] [21] [22]
Source control still matters. Drain an ordinary bacterial abscess, remove infected hardware when indicated, and obtain tissue when it will distinguish infection from malignancy. In cryptococcal meningitis, pressure management with therapeutic LP is essential alongside antifungal therapy.

PCP treatment depends on respiratory severity and is followed by secondary prophylaxis

Confirm with respiratory staining or PCR on an appropriate specimen. PCR may detect colonization; beta-D-glucan supports but does not establish the diagnosis. A normal chest radiograph does not exclude PCP. Consider coinfection. [6]

TMP-SMX is the preferred treatment for most people with HIV-associated PCP, usually for 21 days. IV therapy is generally preferred initially in moderate or severe illness. Oral treatment can be suitable for milder disease or after clinical improvement. Renal function affects the regimen; potassium, creatinine, CBC, liver tests and rash help identify toxicity. [6]

Adjunctive prednisone is indicated for documented or suspected PCP with room-air PaO₂ <70 mm Hg or an A–a gradient ≥35 mm Hg. Begin promptly, ideally within 72 hours of starting PCP treatment. The course is tapered; the linked treatment guidance gives the regimen. [6]

Clindamycin plus primaquine or IV pentamidine are alternatives for moderate or severe disease; atovaquone is an oral option for mild-to-moderate disease. Check G6PD activity before primaquine or dapsone. G6PD deficiency calls for an alternative because of hemolysis and methemoglobinemia risk. When feasible, ART begins within 2 weeks of PCP diagnosis. Secondary prophylaxis begins when the initial treatment course ends. [6]

Before escalating for apparent failure, reassess oxygenation, absorption, toxicity, fluid status, pneumothorax, and another infection. Clinical worsening is not itself proof of resistance.

Cryptococcal meningitis requires antifungal treatment and active pressure management

Send serum and CSF CrAg and CSF fungal culture; measure opening pressure. A negative meningitis-panel PCR does not exclude cryptococcosis. Persistent headache or other signs of raised pressure call for urgent repeat therapeutic LP, at least daily until symptoms improve and opening pressure normalizes. NIH strongly advises considering an early repeat LP within 48 hours in patients without headache. It also advises strongly considering repeat LP within 72 hours when symptoms are minimal or the initial pressure is below 25 cm CSF. Do not use serial CrAg titers to document clearance. [7]

In a U.S. setting with access to electrolyte, renal and hematologic monitoring, preferred CNS induction combines IV liposomal amphotericin B with oral flucytosine, usually for 2 weeks. Flucytosine requires renal adjustment and drug-level monitoring where available. Known complete dihydropyrimidine dehydrogenase (DPD) deficiency is a labeled contraindication. CBC, kidney function, potassium and magnesium track toxicity; follow-up LP at about 1 and/or 2 weeks assesses culture clearance, a separate decision from early pressure management. [7]

After successful induction, fluconazole consolidation lasts at least 8 weeks, before lower-intensity maintenance. A clinically stable patient can start consolidation after the initial 2 weeks while cultures are pending; reducing consolidation intensity requires sterile CSF, clinical stability, and ART initiation. Persistent culture positivity requires reassessment of the antifungal regimen and at least 8 weeks of consolidation counted from documented CSF clearance. Clinical instability is a reason to continue or restart induction rather than advance automatically. [7]

For a person with CNS cryptococcosis who is not already taking ART, treatment for HIV generally begins 4–6 weeks after antifungal initiation. That delay does not apply to all positive serum antigen tests: non-CNS disease follows a separate assessment, with about 2 weeks of antifungal treatment before ART considered prudent. Maintenance can stop only after at least 1 year of antifungal therapy, resolution of symptoms, CD4 ≥100 and suppressed HIV RNA. Therapeutic LPs address symptomatic intracranial hypertension; routine steroids, acetazolamide and mannitol do not substitute for pressure relief. [7]

Fellow and attending discussion

The single-dose liposomal amphotericin strategy studied in African settings includes 14 days of flucytosine and high-dose fluconazole. It is not one-dose monotherapy. The care setting and monitoring requirements matter. [7]

Treat likely toxoplasma encephalitis while preserving a path to another diagnosis

In advanced HIV, multiple enhancing lesions plus positive Toxoplasma IgG support a presumptive diagnosis. MRI is more sensitive than CT. Negative IgG or CSF PCR does not absolutely exclude disease. Consider lymphoma, TB, bacterial abscess, and fungal infection. [5]

Preferred acute options for presumed or confirmed toxoplasma encephalitis include TMP-SMX or pyrimethamine plus sulfadiazine and leucovorin. Leucovorin protects against pyrimethamine-related marrow toxicity. Acute treatment generally lasts at least 6 weeks; extensive disease or incomplete clinical or radiographic response may require longer. [5]

Reconsider the diagnosis and biopsy if deteriorating early or not improving by 10-14 days. Use steroids only for clinically important edema/mass effect; lymphoma can also improve with steroids. Treat seizures if present. [5]

Many clinicians begin ART about 2–3 weeks after toxoplasmosis treatment starts, but there is no trial-defined interval specific to toxoplasma encephalitis. Secondary maintenance, for example with TMP-SMX, follows acute therapy. Stopping requires completion of acute treatment, no symptoms, and CD4 >200 for more than 6 months in response to ART. [5]

Diagnose CMV end-organ disease in the organ involved

Retinitis requires expert retinal examination. Plasma CMV PCR neither confirms nor excludes it. GI disease generally requires compatible endoscopy and tissue evidence; shedding or DNAemia alone is insufficient. Arrange baseline ophthalmology when CD4 <100 and urgent assessment for new visual symptoms. [18]

For retinitis, oral valganciclovir or IV ganciclovir provides systemic induction, generally for 14–21 days and guided by retinal response. Lesions immediately threatening sight require urgent ophthalmology involvement and usually intravitreal therapy in addition to systemic treatment. Maintenance generally uses oral valganciclovir. Renal function and marrow toxicity affect selection and monitoring. [18]

For CMV colitis or esophagitis, IV ganciclovir can transition to oral valganciclovir when absorption is adequate. Treatment generally lasts 21–42 days, until symptoms resolve. Maintenance is usually unnecessary after resolved GI disease unless retinitis, recurrence, or severe initial disease changes that decision. For most end-organ CMV, ART should begin no later than 1–2 weeks after anti-CMV treatment starts. [18]

Retinitis maintenance can stop with ophthalmology after ≥3 months of therapy, inactive lesions, and CD4 ≥100 for ≥3 months on ART. Do not prescribe valganciclovir primary prophylaxis solely for low CD4 or positive blood PCR. [18]

Distinguish disseminated MAC, histoplasmosis, and TB before choosing long treatment

Disseminated MAC

Disseminated MAC requires microbiologic confirmation from blood or involved tissue; a respiratory isolate alone is insufficient. Initial therapy pairs a macrolide with ethambutol to limit resistance. Clarithromycin is one option; azithromycin is an alternative when interactions, intolerance, or feasibility favor it. Macrolide susceptibility matters. Severe or high-burden disease or lack of effective ART can favor adding rifabutin after interaction review. ART should start promptly, preferably when MAC treatment begins. [17]

Treatment is generally at least 12 months. Stopping requires no MAC symptoms and at least 6 months with CD4 >100 and HIV viral suppression on ART. Follow vision/color discrimination with ethambutol, liver tests, QT/interactions, and clinical response. Persistent symptoms require reassessment of cultures, resistance, another infection, lymphoma, or IRIS. [17]

Disseminated histoplasmosis

Consider with fever, weight loss, cytopenias, hepatosplenomegaly, or elevated alkaline phosphatase, especially in the Mississippi/Ohio River valleys. Send urine/serum antigen and obtain fungal cultures or tissue when indicated; antigen cross-reactivity can limit specificity. [19]

For severe disseminated histoplasmosis, liposomal amphotericin B provides induction, generally for at least 2 weeks or until clinical improvement, followed by itraconazole for at least 12 months. Mild-to-moderate disease can usually begin with itraconazole. Formulation, interactions and absorption matter; an itraconazole level after about 2 weeks helps assess exposure. Liver tests, symptoms and serial antigen inform follow-up. CNS disease requires a different, longer induction. ART generally starts promptly after antifungals. [19]

Tuberculosis

Use airborne precautions for suspected pulmonary/laryngeal TB; obtain respiratory AFB smear, culture, NAAT and resistance testing. A negative IGRA does not exclude disease. Standard susceptible-TB therapy uses isoniazid, rifampin, pyrazinamide, and ethambutol initially, then isoniazid/rifampin when eligibility is established. Rifamycin-ART interactions must be resolved before prescribing. [3]

For active TB without suspected meningitis, ART generally starts within 2 weeks of beginning TB treatment if CD4 is below 50, or within 2–8 weeks if CD4 is at least 50. During pregnancy with active TB, start ART as early as feasible regardless of CD4 count, accounting for pregnancy and rifamycin interactions. Suspected TB meningitis requires a separate timing plan. In TB meningitis, early immune recovery can cause dangerous inflammation in a confined space. NIH guidance allows ART after at least 2 weeks of TB treatment once meningitis is controlled by clinical or CSF improvement. ATS/CDC/IDSA guidance has favored waiting until 8 weeks of TB therapy are complete. This difference merits an individualized plan with the TB/HIV team. [3] [48]

Open the TB module for disease-specific treatment choices, duration exceptions, latent infection, resistance, and newer regimens.

Mucosal, enteric, neurologic, and related infections need distinct diagnostic pathways

Additional OIs and related infections
SyndromeDiagnosis and treatmentDecision that changes management
Esophageal candidiasisEsophageal disease requires a systemic antifungal; fluconazole is preferred for 14–21 days when suitable. Oral suspension can help when swallowing is difficult.No improvement within about 7 days warrants endoscopy, culture/speciation, and biopsy for CMV/HSV or another cause. Topical therapy is inadequate. [21]
CryptosporidiosisStool antigen testing, PCR or appropriate staining can support the diagnosis. Rehydration, electrolyte replacement and effective ART are central. Nitazoxanide may be considered as an adjunct; it does not replace immune restoration.Drug evidence in advanced HIV is limited. Do not substitute antiparasitic therapy for immune restoration. [22]
CystoisosporiasisRoutine multiplex panels may omit Cystoisospora, so the stool test must match the suspected pathogen. TMP-SMX is preferred; initial courses in adults commonly last 7–10 days, depending on the regimen and response.Persistent or worsening symptoms warrant reassessment of absorption and response; some patients need longer or more intensive treatment. Maintenance TMP-SMX is indicated when CD4 remains below 200. [23]
MicrosporidiosisSpecial stool studies or tissue testing; ART and supportive care. Treatment depends on species.Albendazole is active for several species but is unreliable for Enterocytozoon bieneusi; confirm species and specialist access options. [24]
PMLProgressive focal deficits, characteristic white-matter MRI lesions, and CSF JCV PCR. Repeat testing or biopsy if suspicion remains despite negative PCR.Initiate effective ART immediately. No established JCV-directed antiviral treatment; edema-producing PML-IRIS may require steroids. [20]
Severe HSV or disseminated VZVLesion PCR and assessment of the involved organs distinguish mucocutaneous, visceral, neurologic and ocular disease. Severe mucocutaneous, visceral or disseminated HSV generally requires initial IV acyclovir; extensive cutaneous or visceral VZV also warrants IV treatment.Adjust for renal function, hydrate, assess CNS/ocular involvement. Nonhealing HSV despite therapy raises resistance; obtain culture/susceptibility and expert treatment. [25] [26]
Bacterial pneumonia or sepsisStandard syndrome-based cultures, imaging, resuscitation, and antibiotics. Broaden for documented resistant-organism risk or severe disease.HIV alone does not justify indefinite MRSA or antipseudomonal therapy. Consider simultaneous PCP/TB and obtain source control when needed. [27]
Syphilis, including ocular or neurologic diseaseInterpret treponemal/nontreponemal tests with prior treatment and symptoms. Stage-appropriate therapy generally matches treatment without HIV.Ocular, otic or neurologic involvement changes the evaluation and treatment. Aqueous crystalline penicillin G given IV for 10–14 days is a recommended neurosyphilis regimen. Benzathine penicillin alone is inadequate. [28]

Refractory mucocutaneous HSV

FDA approved pritelivir (Hovilpri) in October 2026 for immunocompromised adults with mucocutaneous HSV refractory to acyclovir, valacyclovir or famciclovir, with or without documented resistance. The prescribing information describes oral treatment until lesions heal. The pivotal trial excluded ocular, CNS and disseminated HSV; it does not establish a role for pritelivir in those conditions or in VZV. [47]

Acid suppression can reduce pritelivir exposure. Avoid esomeprazole and rabeprazole; other proton-pump inhibitors have product-specific limits. H2 blockers and antacids require specific spacing, and BCRP-substrate interactions require review. The label’s interaction and dosing sections give the exact limits and intervals. No adjustment is recommended for mild through severe renal impairment or Child-Pugh A/B disease; hemodialysis and Child-Pugh C were not evaluated. Human pregnancy and lactation data are absent. Headache and liver-enzyme elevations were reported.

Kaposi sarcoma, lymphoma, medication toxicity, inflammatory disease, and ordinary community infections belong in the differential. A positive low-specificity test should not prevent tissue diagnosis when the clinical picture is inconsistent.

Separate prevention of a first OI from suppression after treatment

Primary prophylaxis and screening
SituationActionStopping or reassessing
PCP: not on ART or starting ART with CD4 <200TMP-SMX is preferred. If Toxoplasma prevention is also indicated, eligibility and regimen choice must cover both organisms; not every PCP regimen does.Usually stop when CD4 ≥200 for ≥3 months on ART. Consider stopping at 100-200 only with sustained undetectable RNA for 3-6 months. For patients on ART, restart if CD4 <100 regardless of RNA, or 100-200 with consistently detectable RNA. [6]
Toxoplasma IgG positive and CD4 <100TMP-SMX can prevent both toxoplasma encephalitis and PCP. Dapsone alone and aerosolized pentamidine do not provide Toxoplasma protection.Primary prophylaxis can stop after CD4 >200 for >3 months with sustained suppression. At CD4 100-200, stopping can be considered after HIV RNA remains undetectable for 3-6 months. These criteria do not apply to secondary prophylaxis. [5]
CD4 <50 and no effective ART or persistent viremiaFor a patient meeting these CD4 and ART criteria without evidence of active MAC, a macrolide such as azithromycin is an option for primary prevention. Active disseminated MAC requires combination treatment.Not recommended when immediately starting effective ART. If mycobacterial blood culture is obtained to exclude disease, wait for the result before prophylaxis. [17]
New HIV diagnosis and CD4 ≤200Screen serum CrAg, particularly if CD4 ≤50. Positive antigen requires assessment for CNS disease and treatment.No routine fluconazole primary prophylaxis in U.S. patients with negative CrAg. [7]
Low CD4 in a Histoplasma-endemic regionExposure reduction and rapid ART. Itraconazole primary prophylaxis is reserved for CD4 <150 plus high-risk occupational exposure or a community incidence >10 cases per 100 person-years.Residence in Missouri alone is not a blanket indication for itraconazole. [19]
CD4 <100 or visual symptomsBaseline retinal examination at <100; urgent ophthalmology for visual change.Do not use routine CMV blood PCR surveillance or valganciclovir prophylaxis. [18]
Secondary suppression stopping criteria
Prior diseaseWhen stopping may be appropriate
PCPUsually CD4 ≥200 for ≥3 months on ART; stopping can be considered at CD4 100–200 if HIV RNA remains undetectable for 3–6 months. If PCP developed at CD4 >200 while on ART, prophylaxis is generally lifelong. [6]
Toxoplasma encephalitisCompleted acute therapy, asymptomatic, CD4 >200 for >6 months on ART. [5]
CryptococcosisAt least 1 year of antifungals, asymptomatic, CD4 ≥100 and suppressed HIV RNA. [7]
Disseminated MACAt least 12 months of treatment, no symptoms, and CD4 >100 with HIV viral suppression for ≥6 months on ART. [17]
CMV retinitisAt least 3 months of treatment, inactive retinal lesions, CD4 ≥100 for ≥3 months; ophthalmology-directed decision and surveillance. [18]
HistoplasmosisAzole treatment >1 year, negative fungal blood cultures, antigen below quantification, undetectable HIV RNA, CD4 ≥150, and ART for ≥6 months. [19]

The maintenance plan should identify the prior disease, the drug, the minimum treatment already completed, the immune recovery needed before stopping, and who will reassess. A threshold for primary prevention cannot be assumed to apply after documented disease. [6] [5] [7] [17] [18] [19]

Clinical worsening after ART is a diagnostic problem before it is an IRIS diagnosis

Unmasking IRIS reveals previously unrecognized infection; paradoxical IRIS worsens a treated infection after immune recovery begins. Reassess adherence, drug exposure, resistance, source control, toxicity, and a second process. The timing and a falling HIV RNA support the context but do not prove IRIS. [3] [7] [17] [5]

Usually continue ART and active antimicrobial treatment while investigating. Mild disease may need symptomatic treatment; severe, organ-threatening inflammation may need corticosteroids and expert management. CNS disease requires particular care. Do not use steroids before considering uncontrolled infection or malignancy. [3] [7] [20]

Fellow and attending discussion

In cryptococcal deterioration, repeat LP with opening pressure and fungal culture. Persistent antigen does not establish microbiologic failure. In apparent toxoplasmosis, steroid-responsive lymphoma can mislead. In MAC, lymphadenitis after ART may reflect IRIS but still requires the clinical and microbiologic context. [7] [5] [17]

Prevention includes PrEP, time-sensitive PEP, and sustained viral suppression

PrEP choices
OptionRoute, population and return visitsRequired safeguards
FTC/TDFOral PrEP for sexual or injection-related risk; protection depends on adherence.Assess renal function, HBV status, HIV testing, and adherence.
FTC/TAFOral PrEP for sexual risk, excluding people likely to acquire HIV through receptive vaginal sex.Review renal function, weight/lipids, HBV, and the population studied.
CabotegravirLong-acting IM PrEP for sexual exposure. After initiation, a reliable return about every 2 months is part of the choice.Antigen-antibody plus HIV RNA testing; plan for missed injections and the long drug tail.
LenacapavirLong-acting SC PrEP for sexually acquired HIV in eligible adults and adolescents weighing ≥35 kg. Oral and injectable components are required at initiation; maintenance visits are every 6 months.Use the current PrEP label and CDC testing schedule. Exclude acute HIV; review interactions and a missed-dose/tail plan.
[29] [30] [31]

Oral PrEP requires renal eligibility and serial HIV testing. For initiation, CDC specifies Cockcroft–Gault estimated creatinine clearance (eCrCl) >60 mL/min for FTC/TDF and ≥30 mL/min for FTC/TAF; reassess kidney function during use. The Truvada label advises against FTC/TDF PrEP below 60 mL/min. Injectable PrEP avoids tenofovir renal exposure but still requires reliable testing and return visits. Never use a prevention-only regimen as HIV treatment. [29] [30] [49]

Nonoccupational PEP is indicated after a substantial exposure when the source has HIV without sustained viral suppression or suppression status is unknown. If the source’s HIV status is unknown, the decision is case by case. When indicated, start as soon as possible, ideally within 24 hours and no later than 72 hours, for 28 days. Pending laboratory or source results should not delay the first dose. Adult options include BIC/FTC/TAF or DTG with an appropriate tenofovir and FTC or 3TC backbone. Baseline testing, contact at about 24 hours, and follow-up Ag/Ab plus NAT at 4–6 and 12 weeks after exposure follow the CDC algorithm. If risk continues, plan transition to PrEP. Occupational exposures follow a separate pathway. [32]

Sustained HIV RNA <200 copies/mL on ART prevents sexual HIV transmission (U=U). It does not prevent other STIs and should not be extrapolated to zero risk for breastfeeding or shared injection equipment. For patients starting ART, use another prevention method for at least 6 months and until HIV RNA <200 is documented; confirm sustained suppression. Support ongoing ART access. [33]

Suppression is the beginning of durable HIV care

Review vaccination history, hepatitis prevention/treatment, STI screening, cancer screening, smoking, blood pressure, metabolic health, bone health, mental health, and substance use. Coordinate HIV-specific cervical and anal screening pathways with available follow-up services. [4] [34]

Use current HIV immunization guidance for influenza, COVID-19, pneumococcal, hepatitis A/B, meningococcal, HPV, recombinant zoster, and exposure-based mpox vaccination. Live MMR and varicella vaccines require adequate immune status; avoid at CD4 <200 and assess pregnancy. Check HBV vaccine response when indicated. [34]

NIH recommends a statin for primary prevention in people with HIV aged 40–75 on stable ART, regardless of LDL cholesterol or estimated ASCVD risk. Use cardiovascular risk and ART interactions to choose the agent and intensity. For primary prevention, defer initiation during pregnancy or when planning pregnancy and stop if pregnancy occurs. [35]

A patient leaving with an ART prescription but no way to obtain it does not have a completed discharge plan. Confirm supply through the first outpatient visit, an actual appointment, pending-result ownership, and a contingency if a dose or visit is missed.

New options expand delivery choices but do not remove eligibility requirements

Long-acting CAB/RPV is a complete injectable maintenance regimen given monthly or every 2 months for appropriately selected patients, generally with HIV RNA <50 for at least 3 months. Review suppression, all resistance and failure history, HBV treatment, pregnancy, interactions, and ability to attend injections. A written bridging and missed-dose plan is part of prescribing. LATITUDE adds evidence for patients with prior adherence challenges after an initial supported oral-treatment phase. [36] [37] [38]

Before switching off tenofovir, check recent HBV serology. Current HBV infection requires continued HBV-active treatment. For an HBsAg-negative, anti-HBc-positive patient switching to a tenofovir-sparing regimen, NIH recommends ALT monitoring every 1–3 months for the first 6 months and every 6 months thereafter. A rise in ALT prompts HBV DNA testing. Confirmed reactivation requires prompt HBV-active therapy alongside a fully suppressive ART regimen. [12] [36]

Lenacapavir has separate prevention and treatment roles. Yeztugo is the prevention product. Sunlenca is used with other active antiretrovirals in heavily treatment-experienced adults with multidrug-resistant HIV; it is not stand-alone treatment or routine initial ART. A long pharmacologic tail can expose virus to functional monotherapy when companion drugs or visits are missed. [31] [39]

The FDA indication for bictegravir/lenacapavir (Bixlenvo) covers adults with HIV RNA <50 copies/mL on stable ART and no known or suspected resistance to either component. This oral switch uses two days of oral Sunlenca loading with Bixlenvo, then Bixlenvo alone for HIV maintenance. When HBV treatment is indicated, preserve it separately.

Doravirine/islatravir (Idvynso) is a switch option for adults with HIV-1 RNA <50 copies/mL on stable ART, no prior virologic treatment failure, and no known doravirine resistance substitutions. It is not an initial or rapid-start regimen and does not treat HBV. The U.S. label does not recommend it at eGFR <30 mL/min/1.73 m² or with Child-Pugh C hepatic impairment; dialysis was not studied. Strong CYP3A inducers and concomitant 3TC or FTC are contraindicated. Rifabutin requires separate supplemental doravirine according to the label, not a second combination tablet. HBV-active therapy must be maintained when indicated. [40]

Fellow and attending discussion

When discussing an investigational strategy, specify the population, stage of development, comparator, and outcome. Longer dosing intervals are not themselves evidence of better clinical outcomes, a cure, or an adequate resistance barrier. The selected updates here are not an exhaustive pipeline review.

Read the endpoint and population before applying a trial

START established the benefit of treatment at high CD4 counts

2015 · Randomized trial · 4,685 adults

Immediate ART versus deferral in asymptomatic adults with CD4 >500. Serious AIDS/non-AIDS events or death occurred in 1.8% versus 4.1%; HR 0.43, 95% CI 0.30-0.62. [41]

Supports treating all people with HIV. It does not answer ART timing during cryptococcal meningitis.

A5164 supports early ART in many acute OIs

2009 · Randomized strategy trial · 282 participants

Early ART at median 12 days versus deferred ART at median 45 days. AIDS progression/death occurred in 14% versus 24%; this was a secondary outcome, and the primary ordered endpoint was not significantly different. [42]

Most participants had PCP; TB was excluded. Do not generalize the average result to every CNS infection.

COAT demonstrates why cryptococcal meningitis is an exception

2014 · Randomized trial · 177 adults

ART at 1-2 weeks versus approximately 5 weeks after diagnosis. Mortality at 26 weeks was 45% versus 30%; HR 1.73, 95% CI 1.06-2.82. [43]

Early immune restoration can harm in this setting. Antifungal regimens and care setting affect applicability, but the trial supports delayed ART.

REPRIEVE supports cardiovascular prevention during treated HIV

2023 · Randomized trial · 7,769 participants

Pitavastatin versus placebo in treated HIV with low-to-moderate cardiovascular risk. MACE rates were 4.81 versus 7.32 per 1,000 person-years; HR 0.65, 95% CI 0.48-0.90. [44]

Muscle symptoms and diabetes were more frequent with pitavastatin. The trial addresses cardiovascular prevention in its enrolled population; the choice of statin still depends on cardiovascular risk and interactions with ART.

PURPOSE 1 established strong preventive efficacy in young women

2024 · Randomized phase 3 trial

No incident HIV infections among 2,134 receiving lenacapavir in the primary analysis; incidence 0 per 100 person-years, 95% CI 0-0.19. Oral FTC/TAF and FTC/TDF groups had infections. [45]

The zero-event finding is an observed trial result, not a guarantee of lifelong or perfect protection. Oral adherence and modeled background incidence matter to interpretation.

PURPOSE 2 extends preventive evidence to men and gender-diverse people

2024 online publication · Randomized phase 3 trial

Two infections in the lenacapavir arm and nine with FTC/TDF in the primary report. The incidence ratio versus estimated background incidence was 0.04 (95% CI 0.01-0.18); versus FTC/TDF, 0.11 (0.02-0.51). [46]

Background incidence is not a randomized untreated control. Breakthrough infection and capsid resistance remain possible.

LATITUDE supports monthly injections after a supported oral phase

2026 · Randomized open-label trial · 453 enrolled in step 1; 306 randomized in step 2

Participants who achieved HIV RNA ≤200 during supported oral treatment could be randomized. Week-48 regimen failure was 22.8% with CAB/RPV versus 41.2% with oral standard care; difference -18.4 percentage points, 98.4% CI -32.4 to -4.3. [38]

The endpoint includes virologic failure or permanent discontinuation. This was not immediate injectable treatment of all unsuppressed patients, and the care support is part of applicability.

Trial summaries use the linked original publications or indexed abstracts. Full-text access was not available for every trial; no unreviewed subgroup analysis is asserted.

Use these cases to practice a defensible next step

Case 1 · An acute viral syndrome with discordant testing

A 26-year-old has fever, rash, pharyngitis, a reactive antigen-antibody screen, and negative antibody differentiation.

What is the next test, and what history changes empiric ART?

Discuss the next step

A reactive screen followed by negative differentiation leaves acute infection possible; HIV RNA and the PrEP/PEP history help resolve it. In a PrEP user with negative antibodies, a low-positive RNA below 200 copies/mL needs confirmation on a new specimen before ART. At RNA ≥200 copies/mL on PrEP, prompt initiation of an effective, complete ART regimen is recommended while confirmation is pending. Prior CAB-LA PrEP specifically raises concern for integrase resistance; if genotype results are pending, boosted darunavir with an appropriate two-NRTI backbone is an interim treatment option. [1]

Case 2 · New HIV with hypoxemic pneumonia

A 42-year-old has CD4 38, diffuse ground-glass opacity, and room-air PaO₂ 62 mmHg.

What should happen today, and when should ART begin?

Discuss the next step

The room-air PaO₂ of 62 mm Hg meets the adjunctive steroid threshold. With a compatible illness and high suspicion, PCP treatment and steroids should begin promptly while respiratory testing, oxygen support, and assessment for bacterial pneumonia or TB proceed. ART generally starts within 2 weeks of PCP diagnosis when feasible. Secondary prophylaxis follows the treatment course. [6]

Case 3 · Headache before rapid ART

A 35-year-old with CD4 24 has 2 weeks of headache and a positive serum CrAg.

Is same-day ART the next step?

Discuss the next step

Headache with positive serum CrAg raises concern for meningitis; antigenemia alone does not establish CNS disease. Urgent CSF evaluation, including opening pressure and fungal culture, helps distinguish the syndromes when LP is safe. Confirmed CNS disease needs prompt antifungals and pressure management; if the person is not already taking ART, HIV treatment generally begins 4–6 weeks after antifungal initiation. [7]

Case 4 · Ring-enhancing lesions that do not improve

A patient with CD4 48, positive Toxoplasma IgG, and multiple lesions receives appropriate therapy but is unchanged at day 14.

What should prevent automatic extension of empiric therapy?

Discuss the next step

Reassess exposure and adherence and pursue alternative diagnoses, particularly CNS lymphoma. Discuss biopsy. A presumptive toxoplasma diagnosis should have a defined reassessment point. [5]

Case 5 · CMV PCR distracts from the involved organ

A patient with CD4 19 has diarrhea and a positive plasma CMV PCR.

Does this establish CMV colitis?

Discuss the next step

No. Obtain a syndrome-directed stool evaluation and consider endoscopy with biopsy. Ask about vision and arrange ophthalmology as indicated. Positive blood PCR does not by itself justify treatment for tissue disease. [18]

Case 6 · Fever and cytopenias before MAC prophylaxis

A patient newly diagnosed with HIV has CD4 12, fever, weight loss, cytopenias, and elevated alkaline phosphatase.

Would primary MAC prophylaxis be appropriate before the cause of the systemic illness is known?

Discuss the next step

The systemic symptoms raise concern for active MAC, histoplasmosis and other causes. Blood cultures for mycobacteria, Histoplasma antigen and tissue when indicated help distinguish them. Macrolide prophylaxis alone could select resistance in undiagnosed active MAC; when a blood culture is sent to exclude disseminated MAC, prophylaxis waits for the result. Severe disseminated histoplasmosis requires prompt liposomal amphotericin-based induction. [17] [19]

Case 7 · A suppressed patient wants fewer pills

A patient with HIV/HBV is suppressed on tenofovir-containing ART and requests CAB/RPV.

What cannot be lost in the switch?

Discuss the next step

HBV treatment. Review resistance and the rest of injectable eligibility, then preserve or separately provide appropriate HBV therapy. CAB/RPV itself does not treat HBV. [12] [36]

Case 8 · A new exposure presents overnight

An HIV-negative patient presents 18 hours after a substantial sexual exposure; the source result is pending.

What action is time sensitive?

Discuss the next step

First assess exposure type and the source’s HIV and suppression status. If the source’s HIV status is unknown, nPEP is a case-by-case decision. At 18 hours an indicated course should start now; pending tests are not a reason to wait. A full 28-day plan includes follow-up HIV testing and discussion of PrEP if future exposure is likely. [32]

Check the decision and explain why it is justified

1. Can a negative antigen-antibody test exclude acute HIV after a recent exposure?

Show explanation

No. Obtain HIV RNA when the exposure and clinical syndrome justify concern; repeat testing as indicated. [1]

2. Can DTG/3TC be the default before HBV and genotype results?

Show explanation

No. Select a suitable rapid-start regimen with HBV activity while those results are pending. [8]

3. Does every patient with CD4 <50 need azithromycin prophylaxis?

Show explanation

No. Effective ART started immediately removes the routine indication; evaluate symptoms for active MAC before prophylaxis. [17]

4. What monitoring item is easy to miss with TMP-SMX?

Show explanation

Potassium, in addition to renal function, blood counts, rash, and other toxicity assessment. [6]

5. Does PCP prophylaxis have the same threshold in untreated and stably treated HIV?

Show explanation

No. For patients not on ART or starting ART, use CD4 <200. Restart decisions on ART incorporate CD4 and the viral-load pattern. [6]

6. Should ART start immediately for cryptococcal meningitis?

Show explanation

Usually no. For a person not already taking ART, cryptococcal meningitis and raised intracranial pressure require treatment first. ART generally starts 4–6 weeks after antifungal therapy begins. [7]

7. Does persistent CrAg mean induction has failed?

Show explanation

No. Follow clinical response, opening pressure, and CSF fungal cultures; antigen can persist. [7]

8. Can a negative plasma CMV PCR exclude CMV retinitis?

Show explanation

No. Retinal examination establishes the diagnosis in the appropriate clinical setting. [18]

9. Can a prevention lenacapavir injection treat established HIV by itself?

Show explanation

No. Treatment requires a fully active combination selected for treatment history and resistance. [39]

10. Does LATITUDE prove that all viremic patients should immediately receive CAB/RPV?

Show explanation

No. Randomization followed an initial supported oral phase and achievement of the trial viral-load threshold. Eligibility and implementation support matter. [38]

11. What is the definitive treatment principle for HIV-associated PML?

Show explanation

Rapid effective ART and immune restoration. There is no established JCV-specific antiviral regimen. [20]

12. What makes the discharge plan complete?

Show explanation

Medication supply through follow-up, a confirmed appointment, named ownership of pending results and toxicity monitoring, and clear return precautions. [2]

Communicate the HIV and OI plans as linked but separate decisions

Consult-note framework

HIV diagnosis and treatment history: [confirmed tests; prior ART/PrEP; prior resistance]. Current HIV RNA [ ] and CD4 [ ]. Current syndrome: [site and severity], with [leading diagnosis] and [alternatives]. Diagnostic plan: [specimens], with [result or reassessment date] that would change treatment. OI treatment: [drug, dose, route, renal adjustment, start date, duration, and maintenance plan]. ART: [complete regimen] starting [date], or deferred because [specific reason and reassessment date]. Monitoring: [toxicity tests and timing], interactions reviewed with [ ]. Prevention: [PCP/toxoplasma/MAC decision], vaccinations and partner prevention as appropriate. Transition: [medication supply], [HIV appointment], [pending-result owner], and [return precautions].

Primary-team communication example

“The pulmonary presentation is concerning for PCP. We are treating while respiratory testing is pending and have assessed the steroid threshold. Please keep the ART plan and start date visible in the discharge summary. Before discharge, we need both the treatment supply and the subsequent prophylaxis prescription, with HIV follow-up confirmed.”

Local confirmation needed: laboratory reflex HIV algorithm and resistance-panel components; access to flucytosine/pyrimethamine and antifungal drug levels; ART formulary and emergency supply; HIV clinic/ADAP access; ophthalmology, endoscopy, TB and public-health contacts.

Sources and evidence review

The sources include U.S. clinical guidance, original trials and product labels. A label defines an approved use; a trial result applies to its enrolled population and comparator. Individual chapters and labels have different revision dates.

  1. Clinical guidance NIH · Early (Acute and Recent) HIV Infection. September 12, 2024. Accessed September 15, 2026.
  2. Clinical guidance NIH · Initiation of Antiretroviral Therapy. September 25, 2025. Accessed September 15, 2026.
  3. Clinical guidance NIH · Mycobacterium tuberculosis. May 02, 2024. Accessed September 15, 2026.
  4. Clinical guidance NIH · Baseline Evaluation. September 21, 2022. Accessed September 15, 2026.
  5. Clinical guidance NIH · Toxoplasma gondii Encephalitis. September 09, 2025. Accessed September 15, 2026.
  6. Clinical guidance NIH · Pneumocystis Pneumonia. May 27, 2026. Accessed September 15, 2026.
  7. Clinical guidance NIH · Cryptococcosis. October 29, 2024. Accessed September 15, 2026.
  8. Clinical guidance NIH · What to Start: Initial Combination Antiretroviral Regimens. Updated September 24, 2026. Accessed October 31, 2026.
  9. Prescribing information Gilead · Biktarvy prescribing information. July 2025. Accessed September 15, 2026.
  10. Clinical guidance NIH · ART Dosing in Renal or Hepatic Insufficiency. September 25, 2025. Accessed September 15, 2026.
  11. Prescribing information ViiV · Dovato prescribing information. October 2025. Accessed September 15, 2026.
  12. Clinical guidance NIH · HBV/HIV Coinfection. Updated September 24, 2026. Accessed November 9, 2026.
  13. Clinical guidance NIH · Initial ART During Pregnancy. March 31, 2026. Accessed September 15, 2026.
  14. Clinical guidance NIH · Virologic Failure. September 12, 2024. Accessed September 15, 2026.
  15. Interaction database University of Liverpool · HIV Drug Interaction Checker. Living source; use revision date displayed in linked document. Accessed September 15, 2026.
  16. Clinical guidance NIH · Plasma HIV-1 RNA and CD4 Monitoring. September 25, 2025. Accessed September 15, 2026.
  17. Clinical guidance NIH · Disseminated Mycobacterium avium Complex. May 27, 2026. Accessed September 15, 2026.
  18. Clinical guidance NIH · Cytomegalovirus Disease. July 14, 2025. Accessed September 15, 2026.
  19. Clinical guidance NIH · Histoplasmosis. October 29, 2024. Accessed September 15, 2026.
  20. Clinical guidance NIH · PML/JC Virus. October 19, 2022; NIH reviewed March 16, 2026. Accessed September 15, 2026.
  21. Clinical guidance NIH · Candidiasis. September 16, 2024. Accessed September 15, 2026.
  22. Clinical guidance NIH · Cryptosporidiosis. January 18, 2023. Accessed September 15, 2026.
  23. Clinical guidance NIH · Cystoisosporiasis. April 23, 2025. Accessed September 15, 2026.
  24. Clinical guidance NIH · Microsporidiosis. November 14, 2023. Accessed September 15, 2026.
  25. Clinical guidance NIH · Herpes Simplex Virus. July 14, 2025. Accessed September 15, 2026.
  26. Clinical guidance NIH · Varicella-Zoster Virus. February 25, 2026. Accessed September 15, 2026.
  27. Clinical guidance NIH · Community-Acquired Bacterial Pneumonia. May 27, 2026. Accessed September 15, 2026.
  28. Clinical guidance NIH · Syphilis. May 27, 2026. Accessed September 15, 2026.
  29. Clinical guidance CDC · Clinical Guidance for PrEP. April 30, 2026. Accessed September 15, 2026.
  30. Clinical guidance CDC · Lenacapavir PrEP Recommendation, 2025. September 18, 2025. Accessed September 15, 2026.
  31. Prescribing information Gilead · Yeztugo prescribing information. August 2026. Accessed September 15, 2026.
  32. Clinical guidance CDC · Nonoccupational PEP Recommendations, 2025. May 8, 2025. Accessed September 15, 2026.
  33. Clinical guidance NIH · ART to Prevent Sexual Transmission. September 25, 2025. Accessed September 15, 2026.
  34. Clinical guidance NIH · Immunizations for Adults and Adolescents With HIV. May 27, 2026. Accessed September 15, 2026.
  35. Clinical guidance NIH · Cardiovascular and Metabolic Complications in People With HIV. Updated October 27, 2026. Accessed November 10, 2026.
  36. Clinical guidance NIH · Optimizing ART in Virologic Suppression. Updated October 27, 2026. Accessed November 10, 2026.
  37. Prescribing information ViiV · Cabenuva prescribing information. November 2025. Accessed September 15, 2026.
  38. Original randomized trial Rana et al. · Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. February 18, 2026. Accessed September 15, 2026.
  39. Prescribing information Gilead · Sunlenca prescribing information. August 2026. Accessed September 15, 2026.
  40. Prescribing information Merck · Idvynso prescribing information. April 2026. Accessed September 15, 2026.
  41. Original randomized trial INSIGHT START Study Group · Initiation of ART in Early Asymptomatic HIV Infection. July 20, 2015. Accessed September 15, 2026.
  42. Original randomized trial Zolopa et al. · Early ART Reduces AIDS Progression/Death in Acute OIs. May 18, 2009. Accessed September 15, 2026.
  43. Original randomized trial Boulware et al. · Timing of ART after Cryptococcal Meningitis. June 26, 2014. Accessed September 15, 2026.
  44. Original randomized trial Grinspoon et al. · Pitavastatin to Prevent Cardiovascular Disease in HIV. July 23, 2023. Accessed September 15, 2026.
  45. Original randomized trial Bekker et al. · Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention. July 24, 2024. Accessed September 15, 2026.
  46. Original randomized trial Kelley et al. · Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. Published online November 27, 2024. Accessed November 9, 2026.
  47. Prescribing information FDA · Hovilpri prescribing information. October 2026. Accessed November 10, 2026.
  48. Clinical guidance NIH · Tuberculosis/HIV Coinfection. September 12, 2024. Accessed November 10, 2026.
  49. Prescribing information FDA · Truvada prescribing information. See sections 2.6 and 5.3. Accessed November 10, 2026.

HIV and OIs · One-page rounds summary

Teaching companion · Edited November 10, 2026. The full module explains eligibility, evidence, and exceptions; linked guidelines and prescribing information give regimen-specific doses.

Confirm and stage

Ag/Ab → differentiation → RNA for discordance. Suspected acute HIV can need RNA despite a negative screen. Obtain CD4, RNA, genotype, organ function, HBV/HCV, and prior ART/PrEP history.

Start appropriate ART

Initial options: BIC/FTC/TAF, DTG + two NRTIs, or eligible DTG/3TC. Baseline RNA >500,000 no longer excludes DTG/3TC. Do not use DTG/3TC for rapid start or before HBV/genotype results. Prior CAB PrEP needs integrase genotype and an appropriate interim regimen. Preserve HBV treatment.

Recognize the OI

Pneumonia: PCP, bacteria, TB. Headache: CrAg/CSF with opening pressure. For cryptococcal meningitis, consider an early repeat therapeutic LP even with low initial pressure. Focal deficit: MRI, toxoplasma/lymphoma/PML differential. Visual symptoms: urgent ophthalmology. Fever/cytopenias: MAC, histoplasmosis, TB, malignancy.

Match ART timing to disease

For people not already taking ART: PCP, start within 2 weeks of diagnosis when feasible; CNS cryptococcosis, usually 4–6 weeks after antifungal initiation. TB without meningitis: start ART within 2 weeks of TB treatment if CD4 <50 or within 2–8 weeks if CD4 ≥50. In pregnancy, start as early as feasible regardless of CD4. TB meningitis requires a separate timing plan. HIV-associated PML: effective ART promptly; no routine CNS-wide delay.

Who needs OI prophylaxis?

PCP primary prophylaxis: CD4 <200 when not on ART or starting ART. Restart on established ART at CD4 <100 regardless of RNA, or at CD4 100–200 with HIV RNA consistently detectable. Primary toxoplasma prophylaxis: IgG positive and CD4 <100. Active MAC must be excluded before primary prophylaxis; effective ART started immediately usually removes the indication. Secondary maintenance has different stopping rules.

Monitor and hand off

TMP-SMX: K+, creatinine, CBC. Amphotericin: renal function, K+/Mg. Flucytosine: CBC, renal adjustment/levels. Check interactions and absorption. Repeat HIV RNA at 4-8 weeks. Confirm medication supply, appointment, and result ownership.

Use prevention opportunities

For a substantial nonoccupational exposure, assess the source. HIV without sustained suppression or with unknown suppression supports nPEP; unknown source HIV status requires a case-by-case decision. Start indicated PEP promptly, within 72 hours, for 28 days. Follow-up testing and transition to PrEP matter when risk continues. Oral PrEP and long-acting CAB or LEN have distinct eligibility and visit requirements. Sustained viral suppression prevents sexual HIV transmission.

Know when to reconsider

No toxoplasma improvement by 10-14 days, new visual loss, rising oxygen need, persistent cultures, or new CNS symptoms require reassessment. Positive CMV blood PCR is not tissue disease; persistent CrAg is not proof of failure.